Last reviewed · How we verify
Foralumab Nasal
Foralumab Nasal is an anti-CD3 monoclonal antibody that modulates the immune system.
Foralumab Nasal is an anti-CD3 monoclonal antibody that modulates the immune system. Used for Moderate to severe ulcerative colitis.
At a glance
| Generic name | Foralumab Nasal |
|---|---|
| Sponsor | Tiziana Life Sciences LTD |
| Drug class | Anti-CD3 monoclonal antibody |
| Target | CD3 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
It works by targeting the CD3 receptor on T cells, leading to a reduction in inflammation and an increase in regulatory T cells. This results in a decrease in the immune system's response to autoimmune diseases.
Approved indications
- Moderate to severe ulcerative colitis
Common side effects
- Nasopharyngitis
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease (PHASE2)
- A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients (PHASE2)
- A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) (PHASE2)
- Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis (PHASE2)
- Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
- Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers (PHASE1)
- In-patient COVID-19 Study of Intranasal Foralumab (PHASE2)
- Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foralumab Nasal CI brief — competitive landscape report
- Foralumab Nasal updates RSS · CI watch RSS
- Tiziana Life Sciences LTD portfolio CI